الفهرس 
EpidemiologyOnly 14 pages are availabe for public view
 |  | from | 32 |  |  |
| | | from | 32 | | |
Abstract
G
astric cancer is one of the most common cancers worldwide (Jemal et al, 2011).
In our study we reviewed of medical records on 102 patients including demographic data and clinic-pathological factors were reported, including age, sex, performance status (ECOG), comorbidities, personal habits, endoscopy and its finding, tumor characteristics, surgery, perioperative treatment, metastatic treatment, treatment response and survival rates were collected.
Among the predisposing factors are: Helicobacter pylori infection, high salt intake, smoking, and in a small percentage of patients, a familial genetic component. More than 95% of stomach cancer cases are adenocarcinomas (Maria, 2013).
Our population under study had: median age of the studied population was 53 years (range: 29-76), male to female ratio as 1.2:1, majority of our patients (88.2%) had good ECOG performance status (≤ 2), (61.8%) of the patients were presented to us with stage IV disease, most common symptoms at presentation were abdominal pain in 58.8% and vomiting in 29.4% and the most common site of gastric cancer was pylorus in 37.3% then fundus in 15.7%.
As regard treatment in patients with locoregional disease, only few patients received neoadjuvant line of treatment while most of non-metastatic patients received adjuvant treatment.
Random assignment of 556 patients to observation alone or adjuvant combined chemoradiotherapy. Three-year disease-free (48 versus 31 %) and overall survival rates (50 versus 41 %) were significantly better with combined modality therapy, and median survival was significantly longer (36 versus 27 months). Benefits were maintained with longer follow up (five-year overall survival 43 versus 28 % [HR= 1.32]. In the chemoradiotherapy group (Smalley et al., 2012).
77.5% of our patients received 1st line metastatic treatment and they gained improvement in PFS (≥ 4 months).
Retrospective review of medical information for 401 patients with newly diagnosed advanced esophageal, GEJ or gastric adenocarcinoma treated with first-line chemotherapy (ECF, ECX or ELF). Median PFS in the ECF or ECX group was 8.48 months [95% CI: 6.87 to 9.86 months]; it was 8.87 months (95% CI: 6.67 to 10.32) in the ELF group (p = 0.6291) (Dechaphunkul et al., 2012).